Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study

Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study

Primary central nervous system lymphoma is a rare but aggressive brain malignancy. It is associated with poor prognosis even with the current standard of care. The aim of this study was to evaluate the effect and tolerability of blood–brain barrier disruption treatment combined with high-dose treatm...

Full description

Bibliographic Details
Main Authors: Hanne K. Kuitunen, Aino L. K. Rönkä, Eila M. Sonkajärvi, Juha-Matti Isokangas, Marja Pyörälä, Kari A. A. Palosaari, Anna S. Jokimäki, Anu E. Partanen, Harri J. Littow, Merja A. Vakkala, Esa J. Jantunen, Mirja E. Huttunen, Katja J. Marin, Annikki M. K. Aromaa-Häyhä, Päivi K. Auvinen, Tuomas Selander, Inka K. Puhakka, Outi M. Kuittinen
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Cancers
Subjects:
BBBD
PCNSL
ASCT
Online Access:https://www.mdpi.com/2072-6694/15/4/1341

Internet

https://www.mdpi.com/2072-6694/15/4/1341

Similar Items